Funding for this research was provided by:
National Cancer Institute (K22CA024439, R00CA188293, U54CA193419)
National Institute of General Medical Sciences (R35GM133712)
National Heart, Lung, and Blood Institute (K08HL128867, R01HL149883)
National Institutes of Health (DP5OD024587)
Received: 15 January 2020
Accepted: 19 August 2020
First Online: 15 September 2020
Ethics approval and consent to participate
: There are no direct clinical activities associated with the study. The study uses primary human samples that were with informed consent and analyzed under the supervision of the Institutional Review Board of Padova University, the Associazone Italiana di Ematologia e Oncologia Pediatrica, and the Berlin-Frankfurt-Münster (AIEOP-BFM) ALL 2000/2006 pediatric clinical trials.
: Informed consent to use leftover material for research purposes was obtained from all of the patients at trial entry in accordance with the Declaration of Helsinki.
: The authors declare that they have no competing interests.